血液肿瘤及造血细胞移植后发热性中性粒细胞减少的抗菌治疗:第10届ECIL推荐
第10届欧洲白血病感染会议(ECIL)针对血液肿瘤或造血细胞移植后发热性中性粒细胞减少患者,推荐基于当地耐药流行率与个体风险因素的个体化抗菌策略,并强调抗菌药物管理和降阶梯治疗。
要点
- 低耐药流行区、血流动力学稳定且无耐药革兰阴性菌定植/感染证据者,推荐避免碳青霉烯或新型β-内酰胺/BLI的经验性单药治疗。
- 重症、血流动力学不稳定、既往有耐药革兰阴性菌定植/感染或高耐药流行区者,需广谱治疗。
- 排除耐药革兰阴性菌感染后应降阶梯,无发热且稳定者完成疗程后无论中性粒细胞计数均建议停药。
核心结论
- 推荐基于当地耐药模式与个体风险因素的个体化经验性及目标性抗菌治疗。
研究设计与样本
- 第10届欧洲白血病感染会议(ECIL)专家小组制定的推荐意见。
主要发现
- 低耐药流行区、血流动力学稳定且无耐药革兰阴性菌定植/感染者,经验性单药治疗可避免碳青霉烯或新型β-内酰胺/BLI。
- 重症、血流动力学不稳定、既往耐药革兰阴性菌定植/感染或高耐药流行区者,需广谱治疗。
关键数值与推荐
- 低耐药流行区稳定患者:经验性单药治疗避免碳青霉烯或新型β-内酰胺±BLI。
- 重症/不稳定/耐药菌定植或高流行区:可选β-内酰胺+氨基糖苷类、碳青霉烯±BLI、抗假单胞菌头孢菌素+BLI或头孢地尔。
- 排除耐药革兰阴性菌感染后降阶梯;无发热且稳定者完成疗程后无论中性粒细胞计数均停药。
临床怎么用
- 临床应结合当地耐药流行率与患者个体风险选择经验性抗菌方案。
- 对稳定低风险患者避免不必要的碳青霉烯或新型β-内酰胺/BLI。
- 排除耐药革兰阴性菌后及时降阶梯,无发热稳定者完成疗程后停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Febrile neutropenia can lead to life-threatening infections in patients with haematological malignancies or after hematopoietic cell transplantation. Infection management is challenged by rising antibiotic resistance and regional differences in bacterial epidemiology. The 10th European Conference on Infections in Leukaemia panel recommends a personalised approach guided by local resistance patterns and individual risk factors. For patients who are haemodynamically stable without colonisation or infection by resistant Gram-negative bacteria in low-resistance prevalence settings, empirical monotherapy sparing carbapenems or novel β-lactams with or without β-lactamase inhibitors (BLI) is recommended. For patients who are critically ill or haemodynamically unstable, those with previous resistant Gram-negative bacteria colonisation or infection, or in high-resistance prevalence settings, broader-spectrum therapy is indicated. Treatment options include β-lactam plus aminoglycoside combinations, carbapenem with or without BLI, anti-pseudomonal cephalosporin and BLI combinations, or cefiderocol, individualised by local epidemiology and patient factors. Antimicrobial stewardship is recommended, including antimicrobial de-escalation once resistant Gram-negative bacteria infection is excluded; and antibiotic discontinuation regardless of neutrophil count, in patients who are afebrile and stable after completing the intended course. We provide treatment strategies for resistant Gram-negative bacteria infections.
引用
- Averbuch D, Vanbiervliet Y, Baccelli F, et al. Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2025. PMID: 41314221. doi:10.1016/S1473-3099(25)00619-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。